Multicenter trial validation of a camera-based method to measure Tc-99m mercaptoacetyltriglycine, or Tc-99m MAG3, clearance

Andrew Taylor, Amita Manatunga, Kathryn Morton, Lionel Reese, Frank S. Prato, Edward Greenberg, Russell Folks, Brad J. Kemp, Margie E. Jones, Patti E. Corrigan, James Gait, Lorie Eshima

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

PURPOSE: To evaluate an improved camera-based method for calculating the clearance of technetium-99m mercaptoacetyltriglycine (MAG3) in a multicenter trial. MATERIALS AND METHODS: Tc-99m MAG3 scintigraphy was performed in 49 patients at three sites in the United States and Canada. The percentage of the injected dose of Tc-99m MAG3 in the kidney at 1-2, 1.0-2.5, and 2-3 minutes after injection was correlated with the plasma-based Tc-99m MAG3 clearances. The data were combined with the results obtained in 20 additional patients in a previously published pilot study. RESULTS: Regression models correlating the plasma-based Tc-99m MAG3 clearance with the percentage uptake in the kidney for each time interval were developed; there was no statistically significant difference among sites in the regression equations. Correction for body surface area statistically significantly (P < .005) improved the correlation coefficient for each time interval. For the 1.0- 2.5-minute interval, the body surface area-corrected correlation coefficient for the four combined sites was .87, and it improved to .93 when one outlier was omitted from the analysis. Similar results were obtained with the other time intervals. Independent processing by two observers showed no clinically important differences in the percentage dose in the kidney or in relative function. CONCLUSION: An improved camera-based method to calculate the clearance of Tc-99m MAG3 was validated in a multicenter trial.

Original languageEnglish (US)
Pages (from-to)47-54
Number of pages8
JournalRadiology
Volume204
Issue number1
StatePublished - Jul 1997
Externally publishedYes

Fingerprint

Technetium Tc 99m Mertiatide
Multicenter Studies
Body Surface Area
Kidney
Radionuclide Imaging
Canada
Injections

Keywords

  • Kidney, failure
  • Kidney, function
  • Kidney, radionuclide studies

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Taylor, A., Manatunga, A., Morton, K., Reese, L., Prato, F. S., Greenberg, E., ... Eshima, L. (1997). Multicenter trial validation of a camera-based method to measure Tc-99m mercaptoacetyltriglycine, or Tc-99m MAG3, clearance. Radiology, 204(1), 47-54.

Multicenter trial validation of a camera-based method to measure Tc-99m mercaptoacetyltriglycine, or Tc-99m MAG3, clearance. / Taylor, Andrew; Manatunga, Amita; Morton, Kathryn; Reese, Lionel; Prato, Frank S.; Greenberg, Edward; Folks, Russell; Kemp, Brad J.; Jones, Margie E.; Corrigan, Patti E.; Gait, James; Eshima, Lorie.

In: Radiology, Vol. 204, No. 1, 07.1997, p. 47-54.

Research output: Contribution to journalArticle

Taylor, A, Manatunga, A, Morton, K, Reese, L, Prato, FS, Greenberg, E, Folks, R, Kemp, BJ, Jones, ME, Corrigan, PE, Gait, J & Eshima, L 1997, 'Multicenter trial validation of a camera-based method to measure Tc-99m mercaptoacetyltriglycine, or Tc-99m MAG3, clearance', Radiology, vol. 204, no. 1, pp. 47-54.
Taylor A, Manatunga A, Morton K, Reese L, Prato FS, Greenberg E et al. Multicenter trial validation of a camera-based method to measure Tc-99m mercaptoacetyltriglycine, or Tc-99m MAG3, clearance. Radiology. 1997 Jul;204(1):47-54.
Taylor, Andrew ; Manatunga, Amita ; Morton, Kathryn ; Reese, Lionel ; Prato, Frank S. ; Greenberg, Edward ; Folks, Russell ; Kemp, Brad J. ; Jones, Margie E. ; Corrigan, Patti E. ; Gait, James ; Eshima, Lorie. / Multicenter trial validation of a camera-based method to measure Tc-99m mercaptoacetyltriglycine, or Tc-99m MAG3, clearance. In: Radiology. 1997 ; Vol. 204, No. 1. pp. 47-54.
@article{9f3f3517f95b4454ad08deb6cb0608e7,
title = "Multicenter trial validation of a camera-based method to measure Tc-99m mercaptoacetyltriglycine, or Tc-99m MAG3, clearance",
abstract = "PURPOSE: To evaluate an improved camera-based method for calculating the clearance of technetium-99m mercaptoacetyltriglycine (MAG3) in a multicenter trial. MATERIALS AND METHODS: Tc-99m MAG3 scintigraphy was performed in 49 patients at three sites in the United States and Canada. The percentage of the injected dose of Tc-99m MAG3 in the kidney at 1-2, 1.0-2.5, and 2-3 minutes after injection was correlated with the plasma-based Tc-99m MAG3 clearances. The data were combined with the results obtained in 20 additional patients in a previously published pilot study. RESULTS: Regression models correlating the plasma-based Tc-99m MAG3 clearance with the percentage uptake in the kidney for each time interval were developed; there was no statistically significant difference among sites in the regression equations. Correction for body surface area statistically significantly (P < .005) improved the correlation coefficient for each time interval. For the 1.0- 2.5-minute interval, the body surface area-corrected correlation coefficient for the four combined sites was .87, and it improved to .93 when one outlier was omitted from the analysis. Similar results were obtained with the other time intervals. Independent processing by two observers showed no clinically important differences in the percentage dose in the kidney or in relative function. CONCLUSION: An improved camera-based method to calculate the clearance of Tc-99m MAG3 was validated in a multicenter trial.",
keywords = "Kidney, failure, Kidney, function, Kidney, radionuclide studies",
author = "Andrew Taylor and Amita Manatunga and Kathryn Morton and Lionel Reese and Prato, {Frank S.} and Edward Greenberg and Russell Folks and Kemp, {Brad J.} and Jones, {Margie E.} and Corrigan, {Patti E.} and James Gait and Lorie Eshima",
year = "1997",
month = "7",
language = "English (US)",
volume = "204",
pages = "47--54",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "1",

}

TY - JOUR

T1 - Multicenter trial validation of a camera-based method to measure Tc-99m mercaptoacetyltriglycine, or Tc-99m MAG3, clearance

AU - Taylor, Andrew

AU - Manatunga, Amita

AU - Morton, Kathryn

AU - Reese, Lionel

AU - Prato, Frank S.

AU - Greenberg, Edward

AU - Folks, Russell

AU - Kemp, Brad J.

AU - Jones, Margie E.

AU - Corrigan, Patti E.

AU - Gait, James

AU - Eshima, Lorie

PY - 1997/7

Y1 - 1997/7

N2 - PURPOSE: To evaluate an improved camera-based method for calculating the clearance of technetium-99m mercaptoacetyltriglycine (MAG3) in a multicenter trial. MATERIALS AND METHODS: Tc-99m MAG3 scintigraphy was performed in 49 patients at three sites in the United States and Canada. The percentage of the injected dose of Tc-99m MAG3 in the kidney at 1-2, 1.0-2.5, and 2-3 minutes after injection was correlated with the plasma-based Tc-99m MAG3 clearances. The data were combined with the results obtained in 20 additional patients in a previously published pilot study. RESULTS: Regression models correlating the plasma-based Tc-99m MAG3 clearance with the percentage uptake in the kidney for each time interval were developed; there was no statistically significant difference among sites in the regression equations. Correction for body surface area statistically significantly (P < .005) improved the correlation coefficient for each time interval. For the 1.0- 2.5-minute interval, the body surface area-corrected correlation coefficient for the four combined sites was .87, and it improved to .93 when one outlier was omitted from the analysis. Similar results were obtained with the other time intervals. Independent processing by two observers showed no clinically important differences in the percentage dose in the kidney or in relative function. CONCLUSION: An improved camera-based method to calculate the clearance of Tc-99m MAG3 was validated in a multicenter trial.

AB - PURPOSE: To evaluate an improved camera-based method for calculating the clearance of technetium-99m mercaptoacetyltriglycine (MAG3) in a multicenter trial. MATERIALS AND METHODS: Tc-99m MAG3 scintigraphy was performed in 49 patients at three sites in the United States and Canada. The percentage of the injected dose of Tc-99m MAG3 in the kidney at 1-2, 1.0-2.5, and 2-3 minutes after injection was correlated with the plasma-based Tc-99m MAG3 clearances. The data were combined with the results obtained in 20 additional patients in a previously published pilot study. RESULTS: Regression models correlating the plasma-based Tc-99m MAG3 clearance with the percentage uptake in the kidney for each time interval were developed; there was no statistically significant difference among sites in the regression equations. Correction for body surface area statistically significantly (P < .005) improved the correlation coefficient for each time interval. For the 1.0- 2.5-minute interval, the body surface area-corrected correlation coefficient for the four combined sites was .87, and it improved to .93 when one outlier was omitted from the analysis. Similar results were obtained with the other time intervals. Independent processing by two observers showed no clinically important differences in the percentage dose in the kidney or in relative function. CONCLUSION: An improved camera-based method to calculate the clearance of Tc-99m MAG3 was validated in a multicenter trial.

KW - Kidney, failure

KW - Kidney, function

KW - Kidney, radionuclide studies

UR - http://www.scopus.com/inward/record.url?scp=1842338685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842338685&partnerID=8YFLogxK

M3 - Article

C2 - 9205222

AN - SCOPUS:1842338685

VL - 204

SP - 47

EP - 54

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 1

ER -